Key result
Finerenone consistently reduces kidney and cardiovascular outcomes vs placebo across baseline SBP quartiles.
Why the study?
This analysis explored the relationship between office systolic blood pressure and cardiorenal outcomes with finerenone in the FIDELIO-DKD trial.
Does finerenone reduce primary kidney and secondary cardiovascular composite outcomes irrespective of baseline systolic blood pressure in patients with type 2 diabetes and chronic kidney disease?
RCT (n=5,669)
Randomized
Does finerenone reduce primary kidney and secondary cardiovascular composite outcomes irrespective of baseline systolic blood pressure in patients with type 2 diabetes and chronic kidney disease?
Finerenone improves cardiorenal outcomes in patients with diabetic kidney disease irrespective of baseline systolic blood pressure, and this benefit is largely independent of its blood pressure-lowering effect.
Answers are grounded in this paper and cite their sources.
Supports finerenone use across SBP levels in T2D-CKD; confirms cardiorenal benefit largely independent of BP reduction.
Background: Chronic kidney disease is frequently associated with hypertension and poorly controlled blood pressure can lead to chronic kidney disease progression. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, significantly improves cardiorenal outcomes in patients with chronic kidney disease and type 2 diabetes. This analysis explored the relationship between office systolic blood pressure (SBP) and cardiorenal outcomes with finerenone in FIDELIO-DKD trial (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease). Methods: Patients with type 2 diabetes, urine albumin-to-creatinine ratio 30 to 5000 mg/g, and estimated glomerular filtration rate of 25 to <75 mL/min per 1.73 m 2 receiving optimized renin-angiotensin system blockade, were randomized to finerenone or placebo. For this analysis, patients (N=5669) were grouped by baseline office SBP quartiles. Results: Finerenone reduced office SBP across the baseline office SBP quartiles, including patients with baseline office SBP of >148 mm Hg. Overall, patients with lower baseline office SBP quartile and greater declines from baseline in SBP were associated with better cardiorenal outcomes. The risk of primary kidney and key secondary cardiovascular composite outcomes was consistently reduced with finerenone versus placebo irrespective of baseline office SBP quartiles ( P for interaction 0.87 and 0.78, respectively). A time-varying analysis revealed that 13.8% and 12.6% of the treatment effect with finerenone was attributed to the change in office SBP for the primary kidney composite outcome and the key secondary cardiovascular outcome, respectively. Conclusions: In FIDELIO-DKD, cardiorenal outcomes improved with finerenone irrespective of baseline office SBP. Reductions in office SBP accounted for a small proportion of the treatment effect on cardiorenal outcomes. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02540993.
No takes yet. Share an insight, caveat, or question.
Ruilope et al. (2022) conducted an RCT in Chronic kidney disease and type 2 diabetes (n=5,669). Finerenone vs. Placebo was evaluated on Primary kidney composite outcome (p=0.87 for interaction). Finerenone consistently reduced primary kidney and cardiovascular outcomes vs placebo across baseline SBP quartiles, with SBP change accounting for 12.6-13.8% of the effect.
Synapse has enriched 10 related papers. Consider them for comparative context: